Kiniksa CFO exercises options, sells KNSA shares

Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa reported option exercises and share sales in the company’s Class A ordinary shares.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa reported option exercises and share sales in the company’s Class A ordinary shares. On February 9, 2026, he exercised options for 8,374 shares at $12.97 and 2,471 shares at $16.90, converting them into the same number of shares.

On the same date, he sold 9,114 shares at a weighted average price of $42.85 and 8,731 shares at a weighted average price of $43.72 through a broker-dealer in multiple trades. These transactions were effected under a Rule 10b5-1 trading plan executed on August 14, 2025. After these trades, he directly held 12,086 Class A ordinary shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Ragosa Mark

Role CHIEF FINANCIAL OFFICER

Sold 17,845 shs ($772K)

Approx. gross sale proceeds $772K

Approx. exercise cost $150K

Type	Security	Shares	Price	Value
Exercise	Share Option	8,374	$0.00	$0.00
Exercise	Share Option	2,471	$0.00	$0.00
Exercise	Class A Ordinary Share	8,374	$12.97	$109K
Exercise	Class A Ordinary Share	2,471	$16.90	$42K
Sale	Class A Ordinary Share	9,114	$42.85	$391K
Sale	Class A Ordinary Share	8,731	$43.72	$382K

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 12,086 shares (Direct)

Footnotes (4)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
4. F4. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KNSA CFO Mark Ragosa report on February 9, 2026?

On February 9, 2026, KNSA CFO Mark Ragosa exercised stock options and sold Class A ordinary shares. He converted options into 8,374 and 2,471 shares, then sold 9,114 and 8,731 shares in broker-executed trades at weighted average prices of $42.85 and $43.72.

How many KNSA options did the CFO exercise and at what exercise prices?

The CFO exercised two tranches of KNSA share options on February 9, 2026. He exercised options for 8,374 shares at $12.97 per share and 2,471 shares at $16.90 per share, both fully vested and exercisable according to the filing’s explanatory footnote.

At what prices did the KNSA CFO sell Class A ordinary shares?

The KNSA CFO sold shares at weighted average prices of $42.85 and $43.72. The filing explains these were executed in multiple broker-dealer trades within ranges of $42.35–$43.345 and $43.35–$44.18, with full trade details available to SEC staff upon request.

How many KNSA shares does the CFO hold after the reported transactions?

After the reported February 9, 2026 transactions, the CFO directly holds 12,086 KNSA Class A ordinary shares. This figure reflects his remaining beneficial ownership following the option exercises that increased his holdings and the subsequent open-market sales that reduced them.

Was the KNSA CFO’s share sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 plan. The plan was executed by the reporting person on August 14, 2025, providing a pre-established framework for trading his Kiniksa Pharmaceuticals International, plc Class A ordinary shares.

What is the nature of the KNSA CFO’s ownership after these transactions?

Following the February 9, 2026 trades, the CFO’s remaining 12,086 KNSA Class A ordinary shares are held with direct ownership. The Form 4 tables list the post-transaction share amounts as “D” for direct ownership and do not indicate any indirect holding structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	02/09/2026		M(1)		8,374	A	$12.97	27,460	D
Class A Ordinary Share	02/09/2026		M(1)		2,471	A	$16.9	29,931	D
Class A Ordinary Share	02/09/2026		S(1)		9,114	D	$42.85(2)	20,817	D
Class A Ordinary Share	02/09/2026		S(1)		8,731	D	$43.72(3)	12,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$12.97	02/09/2026		M(1)			8,374	(4)	09/01/2031	Class A Ordinary Share	8,374	$0	0	D
Share Option	$16.9	02/09/2026		M(1)			2,471	(4)	04/25/2031	Class A Ordinary Share	2,471	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.